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Conclusion: The development of neuropathy in patients with type I
diabetes mellitus is associated with increased triglycerides, increased body
mass index (BMI), smoking, hypertension, and poor glycemic control.
Summary:Glycemic control is the only treatment for diabetic neurop-
athy. The emphasis must be on prevention. Identifying risk factors for
diabetic neuropathy may allow modification of these risk factors and de-
crease the incidence of diabetic neuropathy in patients with diabetes. The
authors studied 1,172 patients with type I diabetes mellitus from 31 centers
involved in the European Diabetes (EURODIAB) Prospective Complica-
tion Study. From 1989 to 1991, neuropathy was assessed at baseline and at
follow up (1997 to 1999). Mean follow up was 7.3  0.6 years. Patients
were evaluated with a standardized protocol, including autonomic function
tests, quantitative sensory testing, and clinical evaluation. In addition, serum
lipids and lipoproteins, urinary albumin excretion rates, and glycosylated
hemoglobin were measured in a core laboratory.
Neuropathy developed in 276 (23.5%) of 1,172 patients who were
initially without neuropathy at baseline assessment. The cumulative inci-
dence of neuropathy was related to the duration of diabetes and the
glycosylated hemoglobin value. Adjusting for duration of diabetes and level
of glycosylated hemoglobin, the authors determined that higher levels of
total and low-density lipoprotein cholesterol and triglycerides, higher von
Willebrand factor levels, higher urinary albumin excretion rates, increased
BMI, hypertension, and smoking were all associated with the cumulative
incidence of neuropathy. When adjustments were made for other risk factors
and diabetic complications, the duration of diabetes, change in glycosylated
hemoglobin values during follow-up, current glycosylated hemoglobin val-
ues, BMI, and smoking remained independently associated with the inci-
dence of neuropathy. The presence of cardiovascular disease at baseline
examination essentially doubled the risk of neuropathy, independent of
cardiovascular risk factors.
Comment: Glycemic control is the only method for treatment of
diabetic neuropathy. The authors have identified potentially modifiable risk
factors for diabetic neuropathy in patients with type I diabetes mellitus. The
obvious hope is that by identifying these risk factors, treatment may lower
the incidence of diabetic neuropathy and subsequent amputations resulting
from complications of neuropathy.
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